Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 19/20 | 0.75 |
| ▸ | CDK9 | P50750 | 6/20 | 0.74 |
| ▸ | CCNK | O75909 | 2/20 | 0.74 |
| ▸ | CDK14 | O94921 | 1/20 | 0.74 |
| ▸ | CDK1 | P06493 | 1/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.74 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.74 |
| ▸ | CDK17 | Q00537 | 1/20 | 0.74 |
| ▸ | CDK18 | Q07002 | 1/20 | 0.74 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15378603 | 0.94 | CCNT1 (0.69) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL1192060 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL12467590 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL1191604 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL12466295 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL12466011 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL12889707 | 0.90 | CCNT1 (0.65) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL1192138 | 0.88 | CCNT1 (0.83) | CCNT1CDK9CCNKCDK14CDK1 | |
| SCHEMBL12850258 | 0.87 | CCNT1 (0.78) | CCNT1CDK9CCNK | |
| SCHEMBL1192234 | 0.87 | CCNT1 (0.71) | CCNT1CDK9CCNKCDK14CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8415381-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415381-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| WO-2012101065-A2 | PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101066-A1 | PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459535-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | CCNT1 76/4885CDK9 1/4885CCNK 39/4885 |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | CCNT1 76/4885CDK9 1/4885CCNK 39/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | CCNT1 76/4885CDK9 1/4885CCNK 39/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | CCNT1 50/4885CDK9 1/4885CCNK 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.